Talazoparib (Tazena) dosage and usage standards and individualized adjustment methods

Talazoparib (Talazoparib) is an oral PARP inhibitor, mainly used for breast and prostate cancer patients carrying BRCA mutations. The standard dose is usually 1 mg orally taken once daily. It is recommended to take it at the same time, with food or on an empty stomach, to maintain stable blood concentration and optimal efficacy. The long half-life of the drug allows it to be administered once a day to maintain sustained PARP inhibition, thereby effectively intervening in the DNA repair mechanism of tumor cells and delaying disease progression.

During the course of medication, monitoring of hematological indicators is very important because talazoparib may cause anemia, leukopenia or thrombocytopenia. For patients who experience moderate hematological adverse reactions, it is usually recommended to temporarily discontinue the drug or reduce the dose to 0.75 mg/day to observe the recovery of the blood picture. Some patients can continue taking the original dose of medication after returning to normal, while some patients may need long-term maintenance of reduced dose therapy to balance efficacy and tolerance.

Patients with liver and kidney dysfunction also require individualized adjustments. For patients with mild to moderate renal impairment, the recommended dose can be maintained at the standard 1 mg/day, but patients with severe renal impairment or dialysis should use it with caution and may need to further reduce the dose or extend the dosing interval. Patients with impaired liver function usually do not need routine dose adjustment, but if they are accompanied by severe liver function abnormalities, the doctor should evaluate whether the dose needs to be adjusted or the medication needs to be stopped based on the blood drug concentration and adverse events.

In addition, individualized medication needs to be combined with the patient's tolerance, age, weight and concomitant medications. For elderly patients or those who have received multi-line therapy for a long time, it is recommended to closely monitor blood images, liver and kidney functions, and adverse events in the early stages of medication so that the dose can be adjusted in a timely manner or the treatment interval can be extended. In general, the dosage and usage of talazoparib should follow the standard protocol and be reasonably adjusted according to individual differences to ensure maximum efficacy while minimizing the risk of adverse reactions.

Reference materials:https://pubmed.ncbi.nlm.nih.gov/39520722/